370 related articles for article (PubMed ID: 18053672)
1. Control and analysis of alkyl esters of alkyl and aryl sulfonic acids in novel active pharmaceutical ingredients (APIs).
Elder DP; Teasdale A; Lipczynski AM
J Pharm Biomed Anal; 2008 Jan; 46(1):1-8. PubMed ID: 18053672
[TBL] [Abstract][Full Text] [Related]
2. Control and analysis of alkyl and benzyl halides and other related reactive organohalides as potential genotoxic impurities in active pharmaceutical ingredients (APIs).
Elder DP; Lipczynski AM; Teasdale A
J Pharm Biomed Anal; 2008 Nov; 48(3):497-507. PubMed ID: 18657926
[TBL] [Abstract][Full Text] [Related]
3. Drug substances presented as sulfonic acid salts: overview of utility, safety and regulation.
Elder DP; Snodin DJ
J Pharm Pharmacol; 2009 Mar; 61(3):269-78. PubMed ID: 19222899
[TBL] [Abstract][Full Text] [Related]
4. Control and analysis of hydrazine, hydrazides and hydrazones--genotoxic impurities in active pharmaceutical ingredients (APIs) and drug products.
Elder DP; Snodin D; Teasdale A
J Pharm Biomed Anal; 2011 Apr; 54(5):900-10. PubMed ID: 21145684
[TBL] [Abstract][Full Text] [Related]
5. A practical derivatization LC/MS approach for determination of trace level alkyl sulfonates and dialkyl sulfates genotoxic impurities in drug substances.
An J; Sun M; Bai L; Chen T; Liu DQ; Kord A
J Pharm Biomed Anal; 2008 Nov; 48(3):1006-10. PubMed ID: 18687555
[TBL] [Abstract][Full Text] [Related]
6. Normal phase and reverse phase HPLC-UV-MS analysis of process impurities for rapamycin analog ABT-578: application to active pharmaceutical ingredient process development.
Chen Y; Brill GM; Benz NJ; Leanna MR; Dhaon MK; Rasmussen M; Zhou CC; Bruzek JA; Bellettini JR
J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Oct; 858(1-2):106-17. PubMed ID: 17826364
[TBL] [Abstract][Full Text] [Related]
7. Review of recent applications of flow injection spectrophotometry to pharmaceutical analysis.
Tzanavaras PD; Themelis DG
Anal Chim Acta; 2007 Apr; 588(1):1-9. PubMed ID: 17386786
[TBL] [Abstract][Full Text] [Related]
8. Determination of arylamines and aminopyridines in pharmaceutical products using in-situ derivatization and liquid chromatography-mass spectrometry.
Vanhoenacker G; Dumont E; David F; Baker A; Sandra P
J Chromatogr A; 2009 Apr; 1216(16):3563-70. PubMed ID: 18804773
[TBL] [Abstract][Full Text] [Related]
9. Analytical control of genotoxic impurities in the pazopanib hydrochloride manufacturing process.
Liu DQ; Chen TK; McGuire MA; Kord AS
J Pharm Biomed Anal; 2009 Sep; 50(2):144-50. PubMed ID: 19427156
[TBL] [Abstract][Full Text] [Related]
10. [Advances on genotoxic impurities of sulfonate esters in pharmaceuticals].
Liu X; Li C; Han H; Zhang W; Chen D
Se Pu; 2018 Oct; 36(10):952-961. PubMed ID: 30378353
[TBL] [Abstract][Full Text] [Related]
11. Determination of methyl and ethyl esters of methanesulfonic, benzenesulfonic and p-toluenesulfonic acids in active pharmaceutical ingredients by solid-phase microextraction (SPME) coupled to GC/SIM-MS.
Colón I; Richoll SM
J Pharm Biomed Anal; 2005 Sep; 39(3-4):477-85. PubMed ID: 15950423
[TBL] [Abstract][Full Text] [Related]
12. Analytical methods for residual solvents determination in pharmaceutical products.
Grodowska K; Parczewski A
Acta Pol Pharm; 2010; 67(1):13-26. PubMed ID: 20210075
[TBL] [Abstract][Full Text] [Related]
13. Recent advances in trace analysis of pharmaceutical genotoxic impurities.
Liu DQ; Sun M; Kord AS
J Pharm Biomed Anal; 2010 Apr; 51(5):999-1014. PubMed ID: 20022442
[TBL] [Abstract][Full Text] [Related]
14. A generic approach for the determination of trace hydrazine in drug substances using in situ derivatization-headspace GC-MS.
Sun M; Bai L; Liu DQ
J Pharm Biomed Anal; 2009 Feb; 49(2):529-33. PubMed ID: 19097722
[TBL] [Abstract][Full Text] [Related]
15. Determination of bisphosphonate active pharmaceutical ingredients in pharmaceuticals and biological material: a review of analytical methods.
Zacharis CK; Tzanavaras PD
J Pharm Biomed Anal; 2008 Nov; 48(3):483-96. PubMed ID: 18599247
[TBL] [Abstract][Full Text] [Related]
16. Overall impact of the regulatory requirements for genotoxic impurities on the drug development process.
Giordani A; Kobel W; Gally HU
Eur J Pharm Sci; 2011 May; 43(1-2):1-15. PubMed ID: 21420491
[TBL] [Abstract][Full Text] [Related]
17. Trace analysis of per- and polyfluorinated alkyl substances in various matrices-how do current methods perform?
Jahnke A; Berger U
J Chromatogr A; 2009 Jan; 1216(3):410-21. PubMed ID: 18817914
[TBL] [Abstract][Full Text] [Related]
18. Residual solvent analysis in hydrochloride salts of active pharmaceutical ingredients.
Puranik SB; Pawar VR; Lalitha N; Pai PN; Rao GK
Pak J Pharm Sci; 2009 Oct; 22(4):410-4. PubMed ID: 19783521
[TBL] [Abstract][Full Text] [Related]
19. Strategies for the identification, control and determination of genotoxic impurities in drug substances: a pharmaceutical industry perspective.
Raman NV; Prasad AV; Ratnakar Reddy K
J Pharm Biomed Anal; 2011 Jun; 55(4):662-7. PubMed ID: 21193280
[TBL] [Abstract][Full Text] [Related]
20. Residues of genotoxic alkyl mesylates in mesylate salt drug substances: real or imaginary problems?
Snodin DJ
Regul Toxicol Pharmacol; 2006 Jun; 45(1):79-90. PubMed ID: 16564608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
